Invion Broadens Photosoft Technology Into Ophthalmology Through Strategic Collaboration.
Invion Limited (ASX: IVX) has partnered with South Korea-based SANGMYUNG Innovation to investigate the potential use of its Photosoft technology for the treatment of wet age-related macular degeneration (wet AMD) and other retinal conditions. The agreement represents Invion’s first expansion into the ophthalmology sector and supports the broader application of its next-generation photodynamic therapy platform.
As part of the collaboration, SANGMYUNG will finance and carry out preclinical studies using selected Photosoft compounds to assess their effectiveness in retinal vascular diseases. Invion will provide the required compounds and light devices while maintaining full ownership of its intellectual property and any future developments arising from the research.
The partnership combines Invion’s therapeutic platform with SANGMYUNG’s advanced eye drug delivery systems, which are designed to improve targeted treatment inside the eye. The companies are aiming to address growing demand for alternative therapies in the expanding global wet AMD market, particularly for patients with limited response to existing treatments.
Customer Notice:
Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.
Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com.au
x
Daily Dose of Buy, Sell & Hold recommendations before the market opens.
Start Your 7 Days Free Trial Now!
We use cookies to help us improve, promote, and protect our services.
By continuing to use this site, we assume you consent to this.
Read our
Privacy Policy
and
Terms & Conditions
Invion Broadens Photosoft Technology Into Ophthalmology Through Strategic Collaboration.
Invion Limited (ASX: IVX) has partnered with South Korea-based SANGMYUNG Innovation to investigate the potential use of its Photosoft technology for the treatment of wet age-related macular degeneration (wet AMD) and other retinal conditions. The agreement represents Invion’s first expansion into the ophthalmology sector and supports the broader application of its next-generation photodynamic therapy platform.
As part of the collaboration, SANGMYUNG will finance and carry out preclinical studies using selected Photosoft compounds to assess their effectiveness in retinal vascular diseases. Invion will provide the required compounds and light devices while maintaining full ownership of its intellectual property and any future developments arising from the research.
The partnership combines Invion’s therapeutic platform with SANGMYUNG’s advanced eye drug delivery systems, which are designed to improve targeted treatment inside the eye. The companies are aiming to address growing demand for alternative therapies in the expanding global wet AMD market, particularly for patients with limited response to existing treatments.
Customer Notice:
Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.
Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com.au